San Francisco, CA (Press Release) – Nektar Thera­peutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clin­i­cal study eval­u­ating NKTR-255, an interleukin-15 (IL-15) re­cep­tor agonist, as mono­therapy for patients with re­lapsed or re­frac­tory non-Hodgkin lym­phoma (NHL) or multiple myeloma (MM). The study will also combine NKTR-255 with multiple targeted anti­bodies, that function through an anti­body-dependent cell-mediated cyto­tox­icity (ADCC) mech­a­nism, to eval­u­ate the safety and efficacy in adults with re­lapsed or re­frac­tory MM. NKTR-255 is designed to activate the IL-15 path­way and ex­pand functionally superior natural killer (NK) cells and promote …

• Ichnos Sciences is a new bio­technology com­pany which is a spin-off of Glenmark Holding SA created to focus on inno­va­tion
• Pipeline in­cludes five novel, first-in-class clin­i­cal-stage assets in on­col­ogy, auto­immune dis­ease and pain
• Company assets in­clude: BEAT® (Bispecific Engagement by Antibodies based on the T cell re­cep­tor), a pro­pri­e­tary plat­form; a devel­op­ment site, two research centers; a GMP biologics manu­fac­tur­ing facility and ~350 employees world­wide

Paramus, NJ (Press Release) – Ichnos ('īk-nōz) Sciences officially opened its doors to the world today as an independent, fully integrated, global bio­tech com­pany. A spin-off of Glenmark Holding SA, a global pharma­ceu­tical com­pany with a track-record of im­prov­ing patients' lives by providing affordable med­i­cines, the newly formed com­pany was first approved in principle by the Glenmark Board of Directors in Feb­ru­ary 2019 and now operates with its own board of directors …

• New funding brings total Series B raise to $75.2 million
• Novo Holdings led round, joined by Venrock, DROIA, Osage University Partners, Lightstone and Celgene Corpo­ra­tion
• RAD51 in­hib­i­tor CYT-0851 now being eval­u­ated in patients with re­lapsed, re­frac­tory B-cell malig­nan­cies and ad­vanced solid tumors

Lexington, MA (Press Release) – Cyteir Thera­peutics, a leader in the discovery and devel­op­ment of next-generation syn­thet­ic lethal ther­a­pies for cancer, today announced the close of an addi­tional $40.2 million in the com­pany's Series B financing, for a total of $75.2 million in this financing. The addi­tional funding will be used to ex­pand the clin­i­cal in­ves­ti­ga­tion of Cyteir's first-in-class RAD51 in­hib­i­tor and lead com­pound, CYT-0851, and to identify new targets using the com­pany's novel gain-of-function syn­thet­ic lethality screen­ing plat­form.

Novo …

Planegg / Munich, Germany, and Shanghai, China (Press Release) – MorphoSys AG (FSE:MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ:MOR) and I-Mab Bio­pharma­ (I-Mab) announced today that I-Mab has received Inves­ti­ga­tional New Drug (IND) clear­ances from the National Medical Products Admin­istra­tion (NMPA) of China to ex­pand the ongoing phase 2 and 3 clin­i­cal trials of MOR202 / TJ202, MorphoSys's human mono­clonal anti-CD38 anti­body for the treat­ment of multiple myeloma (MM), also to mainland China. I-Mab, a China-based clin­i­cal stage bio­pharma­ceu­tical com­pany exclusively focused on the discovery and devel­op­ment of novel or highly dif­fer­en­ti­ated …

Shanghai, China (Press Release) – I-Mab Bio­pharma­ ("I-Mab"), a China and U.S.-based clin­i­cal stage bio­pharma­ceu­tical com­pany exclusively focused on the discovery and devel­op­ment of novel or highly dif­fer­en­ti­ated biologics in immuno-oncology and auto­immune dis­eases and German biopharma com­pany MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX;Nasdaq: MOR), today announced that I-Mab has received Inves­ti­ga­tional New Drug (IND) clear­ances from the National Medical Products Admin­istra­tion (NMPA) of China to ex­pand the ongoing phase II and III clin­i­cal trials of TJ202 / MOR202, MorphoSys's human mono­clonal anti-CD38 anti­body for the treat­ment of multiple …

Gaithersburg, MD (Press Release) – Arcellx, a privately-held bio­pharma­ceu­tical com­pany, to­day an­nounced that it has raised $85 million in an oversubscribed Series B financing. Proceeds will be used to ad­vance the Com­pany’s ARC-T + sparX pro­grams, in­clud­ing clin­i­cal devel­op­ment of a bivalent BCMA-targeted cell ther­apy in mul­ti­ple myeloma, and a CD123-targeted ther­apy in acute myeloid leukemia. The Series B will also fund earlier stage ARC-T + sparX pro­grams for patients with solid tumors and dis­eases outside on­col­ogy.

Participants in the Series B in­clude both existing and new in­vestors to Arcellx. New in­vestors Aju …

Nanjing, China (Press Release) – IASO Biotherapeutics (IASO BIO), a clin­i­cal stage bio­technology com­pany ad­vanc­ing the devel­op­ment of inno­va­tive ther­a­pies for cancer, and Innovent Biologics, Inc. (Innovent) (HKEX:01801), a world-class bio­pharma­ceu­tical com­pany that de­vel­ops and com­mer­cial­izes high quality med­i­cines, an­nounced to­day that IASO BIO has re­ceived National Medical Products Admin­istra­tion (NMPA) ap­prov­al for an Inves­ti­ga­tional New Drug Appli­ca­tion (IND) for CT103A – an inno­va­tive ther­apy for the treat­ment of re­lapsed re­frac­tory mul­ti­ple myeloma (rr/mm) patients. IASO Bio and Innovent will start a Phase Ib/II study to con­firm the R2PD and move to phase II …